Últimas noticias sobre Grifols (NASDAQ:GRFS) Bolsa

Grifols

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

GRFS

Las acciones de Grifols enfrentan retos financieros, pero podrían repuntar tras superar resistencias clave. ¿Qué dicen los análisis?

Acciones de Grifols (GRFS): Barclays recorta precio objetivo, oportunidades en el rebote técnico

CLLNY

REPYY

Los futuros del IBEX 35 y principales índices europeos anticipan subidas tras una semana de volatilidad. ¿Qué impulsará el cierre semanal?

Futuros del IBEX 35 anticipan subidas: ¿Podrá cerrar la semana con un repunte significativo?

Las acciones de Grifols consolidan su valor tras estrategias financieras clave, evitando la dilución y reforzando su competitividad.

Acciones de Grifols (GRFS) evitan dilución: venta de activos y renegociación de deuda explicadas

Grifols, S.A. - American Depositary Shares

Grifols SA

News

Grifols Announced It Has Received A Grant From The Michael J. Fox Foundation For Parkinson's Research To Identify Plasma-based Biomarkers That Could Indicate A Person's Likelihood Of Developing Parkinson's Disease Many Years Before Clinical Diagnosis

<a href="https://www.bloomberg.com/news/articles/2024-12-02/grifols-shareholder-mason-capital-calls-for-board-to-be-replaced?sref=y3YMCJ4e">https://www.bloomberg.com/news/articles/2024-12-02/grifols-shareholder-mason-capital-calls-for-board-to-be-replaced?sref=y3YMCJ4e</a>
<a href="https://www.bloomberg.com/quote/0217620D:US">Mason Capital Management LLC</a>'s Kenneth M Garschina said he wants <a href="https://www.bloomberg.com/quote/GRF:SM">Grifols SA</a>'s board replaced.
The co-founder of the New York-based hedge fund demanded a seat on the Grifols board during <a href="https://www.bloomberg.com/quote/BAM:US">Brookfield Asset Management</a>'s failed attempt to win control of the company. Now he's orchestrating a campaign to revamp the drug maker's board, namely by ousting Tomas Daga, a veteran director and long-time friend of the founding family.

Management

'Grifols Shareholder Mason Capital Calls For Board Overhaul' - Bloomberg News

<h3>Gainers</h3>
<ul>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) shares rose 26.9% to $3.82 during Friday's pre-market session. The market value of their outstanding shares is at $186.6 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock increased by 19.74% to $0.39. The market value of their outstanding shares is at $6.4 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock rose 17.01% to $0.78. The company's market cap stands at $48.1 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock rose 14.44% to $1.03. The market value of their outstanding shares is at $4.6 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock increased by 12.84% to $1.23. The market value of their outstanding shares is at $10.7 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) shares rose 11.76% to $0.95. The company's market cap stands at $62.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) stock fell 74.5% to $2.19 during Friday's pre-market session. The market value of their outstanding shares is at $254.8 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock declined by 13.52% to $4.8. The market value of their outstanding shares is at $100.2 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined by 12.64% to $7.05. The company's market cap stands at $4.7 billion. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock fell 12.38% to $4.25. The company's market cap stands at $47.1 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock declined by 10.37% to $0.54. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares declined by 9.96% to $1.9. The company's market cap stands at $191.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APLT

ARAY

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BMRA

CABA

DERM

IOBT

NTRB

PASG

SILO

TCBP

12 Health Care Stocks Moving In Friday's Pre-Market Session

WIIM

Grifols shares are trading lower after the company ended discussions with Brookfield Capital Partners regarding a potential acquisition.

On Wednesday, Grifols SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition.
This decision follows the company&#8217;s November 19 statement rejecting Brookfield&#8217;s indicative offer to acquire Grifols for 6.45 billion euros ($6.81 billion) or 10.50 euros per Class A share.
Canadian fund Brookfield&nbsp;said it had dropped its plan to take over Spain&#8217;s Grifols&nbsp;due to a disagreement over the pharmaceutical company&#8217;s value, while Grifols said it concurred with the decision, Reuters noted.
The Board of Directors <a target="_blank" href="https://www.grifols.com/en/view-news/-/news/grifols-board-of-directors-announces-termination-of-acquisition-discussions-with-brookfield" rel="noreferrer noopener">determined</a> the proposal undervalued the company&#8217;s growth prospects and long-term potential. Grifols cited strong financial performance as a key factor in its decision.
For the first nine months of 2024, revenue grew 9.1% year-over-year at constant currency, supported by gains across all business units.
The company also reduced debt after selling a 20% stake in Shanghai RAAS for 1.6 billion euros, boosting its financial stability. Adjusted EBITDA for the past 12 months reached 1.7 billion euros.
The company emphasized that Brookfield had full access to its data and management during due diligence but concluded the offer did not reflect Grifols&#8217; true value.
In August, Brookfield Asset Management&nbsp;said it sought 9.5 billion euros ($10.6 billion) in debt financing for a potential take-private <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40489087/brookfield-negotiates-over-10b-in-debt-financing-for-acquisition-of-spanish-pharma-giant-grifols" rel="noreferrer noopener">deal for&nbsp;Grifols</a>.
In a July regulatory filing,&nbsp;Grifols said that&nbsp;Brookfield Capital has confirmed that it has engaged in preliminary discussions with Grifols&#8217;s key shareholders regarding a potential joint offer to delist the company&#8217;s shares from the Spanish stock&nbsp;exchanges and NASDAQ.
The judge of the National Court José Luis Calama has <a target="_blank" href="https://www.poderjudicial.es/portal/site/cgpj/menuitem.65d2c4456b6ddb628e635fc1dc432ea0/?vgnextoid=4426d0e77b343910VgnVCM1000004648ac0aRCRD&amp;vgnextchannel=91fd2ee146f7a210VgnVCM100000cb34e20aRCRD&amp;vgnextfmt=default&amp;vgnextlocale=en&amp;lang_choosen=en" rel="noreferrer noopener">admitted</a> a complaint from the Anti-Corruption Prosecutor&#8217;s Office to investigate Gotham City Research, General Industrial Partners, and several of its directors for allegedly releasing biased and misleading information to the financial market about the credibility of Grifols to induce its investors to sell the shares of this pharmaceutical company, which is listed on the Spanish stock exchange and is part of IBEX, causing a price drop that would generate a profit for the two companies denounced.
In January this year, Gotham City Research released a short report on Grifols, alleging that it manipulated its accounts to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37517028/spanish-healthcare-firm-grifols-hit-with-new-gotham-citys-short-report-faces-questions-regarding-" rel="noreferrer noopener">artificially lower its leverage</a>.
The report alleges that Grifols included satellite companies&#8217; earnings in its accounts but excluded their debts, distorting its leverage ratio.&nbsp;
Price Action: GRFS stock is down 12.9% at $7.03 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42244069/kkr-joins-weave-living-for-strategic-expansion-into-japans-residential-sector" target="_blank" rel="noreferrer noopener">KKR Expands Real Estate Playbook In Japan: New Venture With Weave Living Targets Over 3,000 Residential Units</a></li>
</ul>
Photo via Shutterstock.

Equities

Health Care

Media

Trading Ideas

General

Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?

<h3>Gainers</h3>
<ul>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock increased by 56.6% to $2.13 during Wednesday's pre-market session. The company's market cap stands at $5.7 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares rose 15.18% to $4.02. The company's market cap stands at $169.9 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares moved upwards by 13.24% to $0.42. The market value of their outstanding shares is at $2.7 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock rose 12.65% to $8.99. The market value of their outstanding shares is at $74.2 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) shares increased by 12.29% to $0.34. The company's market cap stands at $5.7 million. </li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) stock increased by 12.2% to $0.37. The company's market cap stands at $3.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) stock fell 80.0% to $0.98 during Wednesday's pre-market session. The market value of their outstanding shares is at $23.1 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 22.88% to $0.56. The market value of their outstanding shares is at $3.8 million. </li>
<li>CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) shares declined by 13.96% to $3.67. The company's market cap stands at $42.0 million. The company's, Q3 earnings came out today. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) stock declined by 12.73% to $7.61. The company's market cap stands at $5.1 billion. </li>
<li>Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) stock fell 10.65% to $169.0. The market value of their outstanding shares is at $5.0 billion. </li>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock fell 9.53% to $2.85. The market value of their outstanding shares is at $121.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLGN

CRVO

CYCN

ENVB

HURA

INSP

MTEM

OTLK

PTIX

RPTX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Contracts

Grifols Held An Extraordinary Meeting This Afternoon, During Which The Content Of A Letter Sent By Brookfield Capital Partners To The Transaction Committee Of The Board Of Directors Was Reviewed, Saying Under The Current Circumstances, Brookfield Is Not In A Position To Proceed With A Potential Offer For Grifols; Board Agrees That It Is Not Feasible For The Transaction To Move Forward

U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday.
Shares of Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/news/earnings/24/11/42201885/dell-technologies-shares-drop-after-q3-revenue-misses-estimates-details">third-quarter results</a>.
Dell Technologies reported quarterly earnings of $2.15 per share, which beat the analyst consensus estimate of $2.05. Quarterly revenue came in at $24.37 billion, which missed the consensus estimate of $24.65 billion and is an increase over revenue of $22.25 billion from the same period last year.
Dell reported better-than-expected earnings for its third quarter, while sales missed estimates.
Dell shares tumbled 13.1% to $123.24 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) shares tumbled 89.2% to $11.65 in pre-market trading after surging 919% on Tuesday.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 17.7% to $7.18 in pre-market trading.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) fell 15% to $2.90 in pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue guidance below estimates</li>
<li>Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) fell 12.7% to $15.13 in pre-market trading after the company reported a year-over-year decrease in third-quarter adjusted EPS results.</li>
<li>Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) shares dipped 10.1% to $242.95 in pre-market trading after the company revised its FY25 subscription revenue guidance.</li>
<li>Frontline plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) shares declined 9.2% to $16.40 in pre-market trading following third-quarter earnings.</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) dipped 8.7% to $35.69 in pre-market trading. HP reported in-line earnings for its fourth quarter, while sales topped estimates. HP said it expects first-quarter adjusted earnings of between 70 cents and 76 cents per share, versus the 85 cent estimate, and fiscal 2025 earnings of between $3.45 and $3.75 per share, versus the $3.60 estimate.</li>
<li>Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) shares declined 8.2% to $292.06 in pre-market trading following third-quarter earnings.</li>
<li>POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) shares declined 7.7% to $4.67 in pre-market trading after announcing a $25 million registered direct offering.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares dipped 5.5% to $344.37 in pre-market trading. CrowdStrike posted upbeat results for its third quarter. The company said it expects fourth-quarter revenue to be between $1.029 billion and $1.035 billion versus estimates of $1.03 billion. The company anticipates fourth-quarter adjusted earnings of 84 cents to 86 cents per share versus estimates of 86 cents per share.</li>
<li>TriMas Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRS#NYSE">TRS</a>) declined 4.2% to $25.31 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

ADSK

CRWD

DELL

PGHL

POET

WDAY

Dell, HP, CrowdStrike, 3D Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Shares of Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/NTNX/news">better-than-expected first-quarter financial results.</a>
Nutanix reported quarterly earnings of 42 cents per share which beat the analyst consensus estimate of 31 cents per share. The company reported quarterly sales of $590.96 million which beat the analyst consensus estimate of $571.78 million.
Nutanix shares jumped 8.8% to $78.71 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) gained 82.1% to $1.12 in pre-market trading.</li>
<li>Cyclerion Therapeutics, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) rose 72.8% to $2.35 in pre-market trading.</li>
<li>Infobird Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) gained 56% to $2.87 in pre-market trading after declining around 6% on Tuesday.</li>
<li>T Stamp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) gained 39.7% to $0.51 in pre-market trading after jumping around 103% on Tuesday.</li>
<li>Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) climbed 24.8% to $21.50 in pre-market trading after dipping more than 20% on Tuesday.</li>
<li>Ambarella, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) gained 24.3% to $85.00 in pre-market trading after the company reported better-than-expected third-quarter financial results.</li>
<li>Creative Media &amp; Community Trust Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) gained 15% to $0.2767 in pre-market trading.</li>
<li>Creative Global Technology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTL#NASDAQ">CGTL</a>) gained 13.6% to $4.44 in pre-market trading. Creative Global Technology priced its IPO at $4 per share.   </li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) gained 10.9% to $2.44 in pre-market trading after dipping 20% on Tuesday. The company announced a registered direct offering of 50 million shares at $2 per unit.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) shares tumbled 89.2% to $11.65 in pre-market trading after surging 919% on Tuesday.</li>
<li>CIMG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMG#NASDAQ">IMG</a>) shares fell 24.4% to $1.21 in pre-market trading after jumping 154% on Tuesday.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 17.7% to $7.18 in pre-market trading.</li>
<li>Blue Star Foods Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) fell 15.6% to $0.3120 in pre-market trading. Blue Star Foods shares jumped 55% on Tuesday after the company announced a $1.5 million buyback program.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) fell 15% to $2.90 in pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Citius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) declined 14.2% to $3.56 in pre-market trading after surging 24% on Tuesday.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) fell 13.1% to $123.24 in today's pre-market trading. Dell reported better-than-expected earnings for its third quarter, while sales missed estimates.</li>
<li>Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) fell 12.7% to $15.13 in pre-market trading after the company reported a year-over-year decrease in third-quarter adjusted EPS results.</li>
<li>Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) shares dipped 10.1% to $242.95 in pre-market trading after the company revised its FY25 subscription revenue guidance.</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) dipped 8.7% to $35.69 in pre-market trading. HP reported in-line earnings for its fourth quarter, while sales topped estimates. HP said it expects first-quarter adjusted earnings of between 70 cents and 76 cents per share, versus the 85 cent estimate, and fiscal 2025 earnings of between $3.45 and $3.75 per share, versus the $3.60 estimate.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

AMBA

BSFC

CGTL

CMCT

CTXR

IDAI

IFBD

NTNX

QMCO

RGTI

Why Nutanix Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock moved upwards by 26.4% to $3.26 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares increased by 19.1% to $3.74. The company's market cap stands at $267.1 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares rose 15.74% to $10.0. The market value of their outstanding shares is at $544.0 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares rose 15.41% to $0.42. The company's market cap stands at $1.4 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares increased by 15.32% to $1.43. The company's market cap stands at $54.0 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) stock rose 14.36% to $1.1. The company's market cap stands at $26.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock fell 16.3% to $0.16 during Tuesday's pre-market session. The market value of their outstanding shares is at $17.8 million. </li>
<li>Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock fell 12.31% to $67.5. The market value of their outstanding shares is at $13.0 billion. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) stock declined by 10.78% to $5.38. The market value of their outstanding shares is at $693.0 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 10.42% to $8.26. The company's market cap stands at $5.6 billion. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 9.8% to $0.26. The company's market cap stands at $1.4 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) stock decreased by 9.26% to $25.0. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRS

ALKS

ALMS

APLM

CTKB

FRES

GCTK

HCWB

INCY

SNOA

TFFP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<a href="https://www.bloomberg.com/news/articles/2024-11-19/grifols-board-issues-unfavorable-opinion-on-brookfield-offer">https://www.bloomberg.com/news/articles/2024-11-19/grifols-board-issues-unfavorable-opinion-on-brookfield-offer</a>
&nbsp;
<a href="https://www.bloomberg.com/quote/GRF:SM">Grifols SA</a>'s board of directors said it won't recommend that shareholders accept <a href="https://www.bloomberg.com/quote/BN:CN">Brookfield Asset Management's</a> indicative offer, which values the Spanish drugmaker at €6.45 billion ($6.8 billion).
The offer "significantly undervalues the company's fundamental prospects and its long-term potential," Grifols said in a <a href="https://www.bloomberg.com/news/terminal/SN7M90MB2SJT">regulatory filing</a> on Tuesday. The asset manager's disclosure was a tentative, non-binding indication requested by the Spanish regulator following media reports.

'Grifols Board Issues Unfavorable Opinion On Brookfield Offer; Brookfield And Grifols Family Have Been In Talks Since July; Investors Are Prepared To Push Back Against Low-Ball Offer' - Bloomberg News

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Tuesday.
Shares of AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/ACM/earnings">fourth-quarter results</a>.
The company reported better-than-expected earnings for its fourth quarter. The company&#8217;s quarterly earnings came in at $1.27 per share which beat the analyst consensus estimate of $1.24 per share. The company reported quarterly sales of $4.11 billion versus the analyst consensus estimate of $4.14 billion.
Aecom shares declined 3.3% to $105.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Hanmi Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) shares tumbled 20.9% to $20.24 in pre-market trading.</li>
<li>Guardian Pharmacy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) fell 20.7% to $16.96 in pre-market trading.</li>
<li>Flushing Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIC#NASDAQ">FFIC</a>) declined 12.2% to $15.25 in pre-market trading.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell 10.3% to $68.98 in today's pre-market trading after the company issued an update on early Phase MRGPRX2 and MRGPRX4 programs.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined 9.1% to $8.38 in pre-market trading.</li>
<li>Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) shares fell 7.3% to $8.37 in pre-market trading after jumping over 20% on Monday.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) fell 5.8% to $30.86 in pre-market trading after jumping around 17% on Monday.</li>
<li>Globalstar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) shares fell 5.8% to $1.61 in pre-market trading. Globalstar announced its board of directors authorized a reverse stock split of its common stock.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>

FFIC

GRDN

GSAT

HAFC

NEXN

Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Brookfield Capital Partners Confirmed Request for Due Diligence Information; Considers €10.50/Share for Grifols Class A Shares; €7.62/Share for Class B Shares

Grifols To Hold Extraordinary Meeting Tuesday To Consider €10.50/Share For Grifols Class A Shares From Brookfield Capital Partners

Grifols shares are trading higher following a report suggesting banks are preparing to submit final offers for a buyout debt deal.

<a href="https://www.bloomberg.com/news/articles/2024-11-14/banks-to-pitch-roughly-11-billion-buyout-debt-deal-for-grifols">https://www.bloomberg.com/news/articles/2024-11-14/banks-to-pitch-roughly-11-billion-buyout-debt-deal-for-grifols</a>
Banks are getting ready to submit final offers to Brookfield Asset Management for a debt package of about €11 billion ($11.6 billion) to back the take-private of Spanish pharmaceutical producer Grifols SA.

Reported Earlier, 'Banks To Pitch Roughly €11 Billion Buyout Debt For Grifols; Lenders Expected To Submit Best And Final Offers Next Week; Takeover Deal Likely To Rank Among Biggest In Europe This Year' - Bloomberg News

Mason Capital Criticizes Grifols Board For Governance Failures And Shareholder Value Loss; Calls For Independent Directors And Improved Oversight; Claims Brookfield Transaction Undervalues Grifols

Grifols shares are trading higher following a report suggesting Brookfield is seeking information on the company's related-party deals and that it is confident it can line up financing

Financing

Brookfield Is Said To Seek Info On Grifols Related-Party Deals; Said To Be Confident It Can Line Up Financing

Grifols shares are trading higher after the company announced it received FDA approval to treat surgical bleeding in pediatric patients with its fibrin sealant solution.

Grifols said to be in talks to restructure debt

Grifols: More Attractive Than In A Very Long Time

Key deals this week: EnLink Midstream, Peabody, StoneCo, UniCredit and more

JPMorgan lowered the firm's price target on Grifols (GRFS) to EUR 9.50 from EUR 14 and keeps a Neutral rating on the shares. Published first on The...

Grifols price target lowered to EUR 9.50 from EUR 14 at JPMorgan

Flat Footed, which holds an aggregate 4.64% of the voting share capital of Grifols (GRFS), sent a letter to the company's board which reads in part...

Grifols holder Flat Footed calls for 'prompt governance overhaul'

Grifols (GRFS) included a term in its $1.4B private debt placement that would allow Brookfield Asset Management (BAM) to refinance the deal early, ...

Grifols debt placement contains clause for Brookfield, Bloomberg says

Berenberg lowered the firm's price target on Grifols (GRFS) to EUR 19.30 from EUR 19.40 and keeps a Buy rating on the shares. Three things matter f...

Grifols shares offer 'compelling buying opportunity,' says Berenberg

Berenberg lowered the firm's price target on Grifols (GRFS) to EUR 15.40 from EUR 15.50 and keeps a Buy rating on the shares. Published first on Th...

Grifols price target lowered to EUR 15.40 from EUR 15.50 at Berenberg

Grifols, S.A. 2024 Q3 - Results - Earnings Call Presentation

Grifols falls as Spanish regulator mulls sanctions against directors

AAUKF

BNCZF

CIXXF

DANOY

DIISF

ENLC

GIFLF

GIFOF

GIKLY

LWAY

PSTX

PUBGY

RHHBF

SFTBY

STNE

UNCRY

Press Releases

Grifols S.A. (GRFS) Admits Improper Accounting, Announces Restatements, Shares Decline Again – Hagens Berman

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga

Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease

Comments

Grifols

Noticias

Últimas noticias sobre Grifols (NASDAQ:GRFS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL